Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CardioComm Solutions Inc V.EKG

Alternate Symbol(s):  EKGGF

CardioComm Solutions, Inc. is a global medical provider of consumer heart monitoring and medical electrocardiogram (ECG) software solutions. The Company’s technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. It develops advanced software, hardware and core laboratory reading services related to ECG and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. Its Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. The Company is also engaged in manufacturing, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It has developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.


TSXV:EKG - Post by User

Bullboard Posts
Post by resourcehorseon Jan 30, 2012 11:31am
194 Views
Post# 19465041

GE Potential

GE Potential

This was posted on the MKI board and illustrates the importance of a company like GE being on board. I like MKI as well, looks like great technology.

A good comparison would be Clarient (OTC: CLRT) which was an otcbb medical diagnostics company that researched non-invasive oncological monitoring and imaging. Similar to Medipattern, Clarient was collaborating with GE Healthcare in the development of Clarient's imaging products. Clarient was a penny stock, and was primarily focused on the research and development of cancer imaging products.

On October 22, 2010. GE Healthcare announced that it would end it's collaboration with Clarient, by purchasing the company in an all cash deal for $580M or $5.00/share.

Similar valuations, considering outstanding common and preferred shares, would value this company near $7.40, if a $580M buyout were to be considered. Now, seeing where we are now, this is optimistic I agree.

However, at these levels ... the market has yet to price in the significance of the Visualize: Vascular product. Clearly, GE Healthcare and Navix Diagnostics have put priority on Medipattern's diagnostic imaging products, something that the market will, in time, come to appreciate. For the market to become more speculative in this stock, they will want to see revenue or earnings growth.

 

 

Bullboard Posts